No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...

The optimization of pharmacokinetic properties is crucial in the design of successful drug candidates. Tune in as Punit Marathe shares the key pharmacokinetic concepts including clearance, volume of ...

Veloxity Labs, a bioanalytical contract research organization (CRO) specializing in accelerating therapeutic development, is proud to announce a partnership with Aplos Analytics. This collaboration ...

A small study on the pharmacokinetic properties of ibuprofen and paracetamol, when taken concurrently, found no significant change in kinetic parameters of the two drugs. [6] Here we report the ...

Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

Dr. Novelli, together with her co-authors, presented "Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial," a sub-study of ...

Intelligent Bio Solutions Inc. INBS recently announced positive initial results from its Pharmacokinetic (PK) study. The study is important for supporting FDA 510(k) clearance of the company’s ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the ...